Prevalence of Hyperparathyroidism Among End-Stage Renal Disease Patients on Regular Hemodialysis and Its Relation to Dialysis Adequacy
| Registry | NCT07820150 |
|---|---|
| Status | Not yet recruiting |
| Study type | Observational |
| Enrollment | 130 (Estimated) |
| Sponsor | Assiut University (Other) |
| Conditions | Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Chronic Kidney Diseases |
| Dates | start 2026-09-10 (estimated), primary completion 2027-09-10 (estimated), completion 2028-03-01 (estimated), first posted 2026-09-15, last updated 2026-09-15 |
Related Papers Related Patents Related Grants Related Experts
All trials for Hyperparathyroidism, Secondary All trials for Kidney Failure, Chronic
This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut University Hospitals.
Secondary hyperparathyroidism is a common complication of end-stage renal disease and is associated with bone disease, vascular calcification, and increased mortality. Dialysis adequacy, measured by spKt/V and urea reduction ratio (URR), may influence phosphate control and parathyroid hormone levels.
This observational cross-sectional study will include adult patients with end-stage renal disease maintained on regular thrice-weekly hemodialysis for at least three months. Dialysis adequacy will be assessed by spKt/V and URR. Serum intact parathyroid hormone (iPTH) and mineral parameters will be measured.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Single cohort: ESRD patients on regular hemodialysis | Adult patients with end-stage renal disease on regular thrice-weekly hemodialysis who will undergo assessment of dialysis adequacy (spKt/V and URR) and measurement of serum intact parathyroid hormone and mineral parameters. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * \- Age 18 years or older * Diagnosed with end-stage renal disease * Maintained on regular thrice-weekly hemodialysis for at least three consecutive months * Written informed consent Exclusion Criteria: * \- Primary hyperparathyroidism or prior parathyroidectomy * Active severe infections or acute systemic illnesses * Active malignancy * Severe hepatic dysfunction or chronic liver cirrhosis